2023

• DEC Awarded 20^th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
• JUL Achieved 2^nd Place in the BioAsia 2023 National Science Council “New Business Incubation Exhibition Selection”
• MAY Awarded 2023 NBRP DEMODAY – Investor’s Choice Award (EF-001: Cerebraca® Wafer – GBM)
• APR Taipei Headquters established

2022

• DEC Awarded 19^th National Innovation Award – Clinical innovation (EF-001: Cerebraca® Wafer – GBM)

2021

• DEC 
  
  • Awarded 18^th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
  • Awarded 18th National Innovation Award – Excelsior Award (HK-001: ALS)
  • Awarded 18th National Innovation Award (EF-009: EF-009 Wafer – Pancreatic Cancer)

2020

• DEC Awarded 17th National Innovation Award (EF-011: Pulmonary fibrosis)
• JAN IND application approved by TFDA (EF-009: EF-009 Wafer – Pancreatic Cancer)

2019

• DEC
  • Awarded 16^th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
  • Awarded 16^th National Innovation Award – Excelsior Award (HK-001: ALS)
  • Awarded 16^th National Innovation Award (EF-012: Immunomodulatory therapy for cancer)

• OCT
  • IND application approved by USFDA (EF-009: EF-009 Wafer – Pancreatic Cancer)
  • Congress of Neurological Surgeons – selected late-breaking presentation with the highest score  (EF-001: Cerebraca® Wafer – GBM)

• JUL Taipei Biotech Awards – Innovation Award (EF-001: Cerebraca® Wafer – GBM)
• FEB IND application approved by TFDA (HK-001: ALS)

2018

• FEB IND application approved by USFDA (HK-001: ALS)

2017

• NOV Awarded 14^th National Innovation Award (HK-001: ALS)
• SEP Received funding from the Ministry of Economic Affairs’ Fast Track Program (EF-001: Cerebraca® Wafer – GBM)

2016

• NOV IND application approved by TFDA (EF-001: Cerebraca® Wafer – GBM)
• AUG IND application approved by USFDA (EF-001: Cerebraca® Wafer – GBM)
• JAN Everfront Biotech Inc. is qualified by the qualified for governmental incentives under Biotech and New Pharmaceutical Development Act in Taiwan

2015

• AUG Orphan drug Designation Granted by USFDA (EF-001: Cerebraca® Wafer – GBM)

2014

• DEC
  • Awarded 11^th National Innovation Award (EF-001: Cerebraca® Wafer – GBM)
  • Received funding support from the A+ Enterprise Innovation R&D Program of the Ministry of Economic Affairs (HK-001: ALS)

2013

• MAY Received funding from the Ministry of Economic Affairs for the Science and Technology Development Program (EF-001: Cerebraca® Wafer – GBM)

2010

• DEC Everfront Biotech Inc. was formally established by President Ho-Ching Chen, with Dr. Chou Pei-Wen serving as Chairman and General Manager. Dr. Shinn-Zong Lin, Dr. Horng-Jyh Harn, and Dr. Tzyy-Wen Chiou were invited to join the scientific advisory board, and Dr. Tza-Zen Chuang was appointed to the consulting advisory team